Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · BlossomHill Therapeutics, Inc. (BLSM)

BlossomHill Reports 45% Response Rate for BH-30643 in EGFR C797S Lung Cancer Data

Positive Impact 3 of 5 product/contract Written later

BlossomHill Therapeutics presented updated Phase 1/2 SOLARA trial data for its investigational EGFR inhibitor BH-30643 in lung cancer patients with the EGFR C797S resistance mutation, at the IASLC 2026 World Conference on Lung Cancer. The filing reports a 45% objective response rate in 40 patients, which the company says has no approved targeted therapy, and it plans a Phase 2 study starting in Q1 2027.

Key points

  • Objective response rate of 45% (18 of 40 patients, 95% CI 29%-62%); disease control rate of 88% (35 of 40) as of the May 12, 2026 data cutoff
  • Treatment-related dose reductions and discontinuations occurred in 9% and 3% of 174 patients treated at 40 mg, 50 mg and 60 mg twice daily
  • Median follow-up was 6.9 months; the company plans a global Phase 2 study in EGFR C797S-positive NSCLC in Q1 2027
  • Presentation follows FDA Fast Track designation for BH-30643 in advanced or metastatic EGFR C797S-positive NSCLC

The filing

CompanyBlossomHill Therapeutics, Inc. (BLSM)
Form8-K, current report
Filed with the SECSep 15, 2026, 7:30 AM ET
Accession number0001193125-26-391328

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:45 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 15, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.